Mammographic findings in different breast cancer subtypes (luminal, Her2 positive, triple negative)

被引:0
|
作者
Pourali, L. [1 ]
Sales, S. Shahid [2 ]
Taghizadeh, A. [2 ]
Pezeshkirad, M. [3 ]
Farokh, D. [3 ]
Andakhshideh, E. [4 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Dept Obstet & Gynecol, Mashhad, Iran
[2] Mashhad Univ Med Sci, Fac Med, Dept Clin Oncol, Mashhad, Iran
[3] Mashhad Univ Med Sci, Fac Med, Dept Radiol, Mashhad 4, Iran
[4] Mashhad Univ Med Sci, Mashhad 4, Iran
来源
关键词
Breast cancer; immunohistochemistry; mammography; FEATURES;
D O I
10.18869/acadpub.ijrr.16.2.251
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Prognosis and management of breast cancer are defined by different variables including histological type, grading, clinical stage, Her2+, estrogen and progesterone receptor conditions. Generally, mammography is one of the most important imaging which is done in breast cancer patients. The aim of this research was to evaluate different mammographic patterns in different breast cancer sub types. Materials and Methods: Demographic and clinicopathologic data of 128 breast cancer patients which referred to two academic hospitals were obtained from their registered files and their mammographies were reviewed by two radiologists separately. Patients were categorized into 3 groups of Luminal, triple negative and Her2+ and the checklists were filled out by research team. The mentioned data was then analyzed by the SPSS software version 16. Results: In this study we found significant difference in margins' clarity and axillary lymphadenopathy between mammographic presentations of different breast cancer subtypes (P=0.041) and (P=0.14), respectively; but the difference of other mamographic presentations including mass existence, mass size, margin type, peleomorphic calcification, micro calcification, nipple retraction, skin thickening and tissue distortion were not significantly different between three groups (P>0.05). Conclusion: Results of current study showed no significant difference between mammographic features of different invasive breast cancer subtypes except for axillary lymphadenopathy and ill-defined margins. Since the majority of patients were in premenopausal status; perhaps we can say lower sensitivity of mammography in premenopausal women couldn't accurately distinguish mammographic differences between invasive breast cancer subtypes in this study.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 50 条
  • [21] Cytoplasmic Beta-Catenin Expression Associated with Triple Negative and HER2 Positive Breast Cancer Subtypes in African-American Women
    Esnakula, A. K.
    Ricks-Santi, L. J.
    Kannan, Y. M.
    Naab, T. J.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 37A - 38A
  • [22] Cytoplasmic Beta-Catenin Expression Associated with Triple Negative and HER2 Positive Breast Cancer Subtypes in African-American Women
    Esnakula, A. K.
    Ricks-Santi, L. J.
    Kannan, Y. M.
    Naab, T. J.
    [J]. MODERN PATHOLOGY, 2012, 25 : 37A - 38A
  • [23] Nuclear localization of NRF2 in stroma of HER2 positive and triple-negative breast cancer
    Oresic, Tomislav
    Bubanovic, Sanda
    Ramic, Snjezana
    Sarcevic, Bozena
    Gasparovic, Ana Cipak
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [24] Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
    Ji, L. Min
    Ho, B. Seung
    Lee, S. E.
    Kook, Y.
    Moon, S.
    Kim, J.
    Kim, M. J.
    Bae, S. J.
    Jeong, J.
    Ahn, S. G.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S303 - S303
  • [25] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [26] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [27] The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer
    Ramakrishna, M.
    Martin, S.
    Campbell, P. J.
    Futreal, P. A.
    Stratton, M. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S132 - S132
  • [28] A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
    Xue Yang
    Artem Smirnov
    Oreste Claudio Buonomo
    Alessandro Mauriello
    Yufang Shi
    Julia Bischof
    Jonathan Woodsmith
    Gerry Melino
    Eleonora Candi
    Francesca Bernassola
    [J]. Cell Death Discovery, 9
  • [29] A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
    Yang, Xue
    Smirnov, Artem
    Buonomo, Oreste Claudio
    Mauriello, Alessandro
    Shi, Yufang
    Bischof, Julia
    Woodsmith, Jonathan
    TOR CENTRE, Francesca
    Melino, Gerry
    Candi, Eleonora
    Bernassola, Francesca
    [J]. CELL DEATH DISCOVERY, 2023, 9 (01)
  • [30] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)